Continuing to strengthen FDA's science approach to emerging technologies |
| |
| Authors: | Rachael Anatol Steven Bauer Suzanne Epstein Ross Filice Kristina Lauritsen Mark H Lee Elizabeth Mansfield Michelle McMurry-Heath Joseph Milone Carlos Peña Steven Pollack Issam Zineh |
| |
| Affiliation: | Emerging Technology Programs, Office of the Commissioner, Food and Drug Administration, Silver Spring, MD, USA |
| |
| Abstract: | Emerging technologies result when advances and innovation in technology lead to discoveries. Often emerging technologies stimulate novel research in medical product development that contribute to new approaches to manufacturing and can improve the quality of products. By supporting investments in agency coordination, staff training and professional development, regulatory science research, stakeholder engagement, and enhancing opportunities for expert input, the U.S. Food and Drug Administration plays a critical role in translating innovations into novel safe and effective medical products that improve the public health. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
